Randomized Evaluation of Nonhealing Diabetic Foot Ulcers With Exclusive Wound Therapy

Launched by SEQUENCE LIFESCIENCE, INC. · Jul 24, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment approach for people with diabetic foot ulcers—open sores on the feet that can be slow to heal in people with diabetes. The goal is to see if using a special combination of wound therapies, along with standard care, helps these sores close completely within 12 weeks, compared to usual treatment alone.

To join the study, participants must be adults with type 1 or type 2 diabetes who have a foot ulcer that has not healed after at least four weeks of regular care. The sore must be a certain size and located mostly below the ankle. People with serious infections, exposed bone or tendon in the ulcer, or other health issues that affect healing are not eligible. Participants will need to follow a treatment plan that includes using offloading devices—tools that help take pressure off the sore—and attend weekly visits for check-ups and wound measurements. This study is currently recruiting adults aged 18 and older, and it aims to find better ways to help difficult-to-heal diabetic foot ulcers heal more effectively.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • The potential subject must be at least 18 years of age or older.
• • The potential subject must have a diagnosis of type 1 or 2 Diabetes mellitus.
• • At enrollment, the potential subject must have a target ulcer with a minimum surface area of 1.0 cm2 and a maximum surface area of 15.0 cm2 measured post debridement with the imaging device length times width.
• • The potential subject must have a target ulcer that has been present for a minimum of 4 weeks of standard of care, prior to the initial screening visit.
• • The potential subject must have a target ulcer located on the foot with at least 50% of the ulcer below the malleolus.
• • The potential subject must have a target ulcer that is Wagner 1 or 2 grade, extending at least through the dermis or subcutaneous tissue and may involve the muscle provided it is below the medial aspect of the malleolus. The ulcer may not include exposed tendon or bone.
• * The potential subject's affected limb must have adequate perfusion confirmed by vascular assessment. Any of the following methods performed within 3 months of the first screening visit are acceptable:
• • 1. ABI between 0.7 and ≤ 1.3;
• • 2. TBI ≥ 0.6;
• • 3. TCOM ≥ 40 mmHg;
• • 4. PVR: biphasic. 8. If the potential subject has two or more ulcers, they must be separated by at least 2 cm. The largest ulcer satisfying the inclusion and exclusion criteria will be designated as the target ulcer.
• • The potential subject must have a target ulcer located on the 50% below the malleolus and not on the dorsal toes.
• • The ulcer must be offloaded for at least 14 days prior to enrollment.
• • The potential subject must consent to using the prescribed offloading method for the duration of the study.
• • The potential subject must agree to attend the weekly study visits required by the protocol.
• • The potential subject must be willing and able to participate in the informed consent process.
• Exclusion Criteria:
• • The potential subject is known to have a life expectancy of \< 6 months.
• • The potential subject's target ulcer is not secondary to diabetes.
• • The target ulcer is infected or there is cellulitis in the surrounding skin.
• • The target ulcer exposes tendon or bone.
• • There is evidence of osteomyelitis complicating the target ulcer.
• • The potential subject is receiving immunosuppressants (including systemic corticosteroids at doses greater than 10 mg of prednisone per day or equivalent) or cytotoxic chemotherapy or is taking medications that the PI believes will interfere with wound healing (e.g., biologics).
• • The potential subject has applied topical steroids to the ulcer surface within one month of initial screening.
• • The potential subject with a previous partial amputation on the affected foot that results in a deformity that impedes proper offloading of the target ulcer.
• • The potential subject has glycated hemoglobin (HbA1c) greater than or equal to 12% within 3 months of the initial screening visit.
• • The surface area of the potential subject's target ulcer has reduced in size by more than 20% in the 2 weeks prior to the initial screening visit ("historical" run-in period). Imaging Device is not required for measurements taken during the historical run-in period (e.g., calculating surface area using length X width is acceptable).
• • The surface area measurement of the potential subject's target ulcer decreases by 25% or more during the active 2-week screening phase: the 2 weeks from the initial screening visit (S1) to the TV-1 visit during which time the potential subject received SOC.
• • The potential subject has an acute Charcot foot, or an inactive Charcot foot, which impedes proper offloading of the target ulcer.
• • The potential subject is a woman who is pregnant or considering becoming pregnant within the next 6 months.
• • The potential subject has end stage renal disease requiring dialysis.
• • The potential subject has participated in a clinical trial involving treatment with an investigational product within the previous 30 days.
• • The potential subject, in the opinion of the investigator, has a medical or psychological condition that may interfere with study assessments.
• • The potential subject was treated with hyperbaric oxygen therapy (HBOT) or a Cellular, Acellular, Matrix-like Product (CAMP) in the 30 days prior to the initial screening visit.
• • The potential subject has a malnutrition.
• • The potential subject has a known allergy or sensitivity to PBS, IPA, processing solutions, reagents, or latex.